Hepatic Resection for Huge (>15 Cm) Multinodular HCC with Macrovascular Invasion
Overview
Affiliations
Background: Surgical resection has routinely not been recommended for patients with huge (>15 cm) multinodular lesions and macrovascular invasion (advanced-stage hepatocellular carcinoma [HCC] patients) because of high operative mortality, recurrence rate, and lack of survival benefit.
Methods: A retrospective study of 1425 patients was carried out, of which 1245 patients met EASL/AASLD criteria for hepatic resection (HR-EA group), 116 were surgically treated advanced-stage HCC patients (HR-AS group), and 64 were advanced-stage HCC patients receiving nonsurgical treatments (N-AS group).
Conclusion: HR may still be suitable for the HCC patients with huge (>15 cm) multinodular lesions and macrovascular invasion in selected cases. Advanced-stage HCC patients without liver cirrhosis and with a tumor-free resection margin could enjoy longer survival and lower recurrence. Preoperative and/or postoperative TACE provides no survival benefits for advanced-stage HCC patients.
Pandrowala S, Patkar S, Goel M, Mirza D, Mathur S Langenbecks Arch Surg. 2023; 408(1):144.
PMID: 37041364 DOI: 10.1007/s00423-023-02881-w.
Miki A, Sakuma Y, Ohzawa H, Saito A, Meguro Y, Watanabe J World J Gastroenterol. 2022; 28(38):5614-5625.
PMID: 36304091 PMC: 9594014. DOI: 10.3748/wjg.v28.i38.5614.
Outcome after Resection for Hepatocellular Carcinoma in Noncirrhotic Liver-A Single Centre Study.
Penzkofer L, Mittler J, Heinrich S, Wachter N, Straub B, Kloeckner R J Clin Med. 2022; 11(19).
PMID: 36233670 PMC: 9570688. DOI: 10.3390/jcm11195802.
Wee J, Tee C, Junnarkar S, Low J, Tan Y, Huey C J Clin Transl Res. 2022; 8(3):209-217.
PMID: 35813892 PMC: 9260342.
Wang Z, Mu K, Lv Y, Zhao L, Li B, Hao Y Ir J Med Sci. 2022; 191(6):2493-2499.
PMID: 35064533 DOI: 10.1007/s11845-021-02851-5.